The FDA approved Bosulif for children aged 1 and older with newly diagnosed or resistant/intolerant chronic myelogenous leukemia. The Food and Drug Administration ...
A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...
Novartis Canada is pleased to announce that Scemblix® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario’s new ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...
Credit: Getty Images. A new capsule dosage form has also been approved in 50mg and 100mg strengths. The Food and Drug Administration (FDA) has approved Bosulif ...
The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...
By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete ...
Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback